TABLE 1.
Details of marmosets used to assess the virulence of two strains of MERS-CoV by different routes of challengea
| Study and marmoset ID | Challenge strain | Challenge route | Challenge dose (PFU) | Time to fever (h) | Duration of fever (h) |
|---|---|---|---|---|---|
| Study 1 | |||||
| 91W | EMC/2012 | Aerosol | 3.20 × 103 | 47.2 | 20.1 |
| 55W | 2.40 × 103 | 56.8 | 11.0 | ||
| 22X | Intranasal | 9.50 × 105 | 328.8 | 43.2 | |
| 46X | 9.50 × 105 | NA | NA | ||
| 14X | Oral | 9.50 × 106 | NA | NA | |
| 110W | 9.50 × 106 | NA | NA | ||
| 56W | England 1 | Intranasal | 6.60 × 105 | NA | NA |
| 63W | 6.60 × 105 | NA | NA | ||
| 27X | Oral | 6.60 × 106 | NA | NA | |
| 30X | 6.60 × 106 | NA | NA | ||
| 48X | Aerosol | 2.20 × 103 | NA | NA | |
| 137X | 1.40 × 103 | 310 | 30 | ||
| Study 2 | |||||
| 35X | EMC/2012 | Aerosol | 3.45 × 105 | 26.8 | 41.4 |
| 29X | 2.30 × 105 | 28.0 | 40.7 | ||
| 130X | 1.11 × 106 | 21.6 | 25.1b | ||
| 146X | 4.42 × 105 | 21.6 | 27.1b | ||
a
NA, not applicable.
b
Euthanized during fever for a scheduled time point.